Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The role of MEK inhibitors in the treatment of metastatic melanoma
Antonio M. Grimaldi, Ester Simeone, Paolo A. Ascierto
Current Opinion in Oncology (2014) Vol. 26, Iss. 2, pp. 196-203
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
Peter Ebert, Jeanne Cheung, Yagai Yang, et al.
Immunity (2016) Vol. 44, Iss. 3, pp. 609-621
Open Access | Times Cited: 642
MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
Pui–Kei Wu, Jong–In Park
Seminars in Oncology (2015) Vol. 42, Iss. 6, pp. 849-862
Open Access | Times Cited: 123
Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
Gang Zheng, Li‐Hui Tseng, Guoli Chen, et al.
BMC Cancer (2015) Vol. 15, Iss. 1
Open Access | Times Cited: 97
Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance
William Wagstaff, Rimel N. Mwamba, Karina Grullon, et al.
Genes & Diseases (2022) Vol. 9, Iss. 6, pp. 1608-1623
Open Access | Times Cited: 45
Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors
Mark Merchant, John G. Moffat, Gabriele Schaefer, et al.
PLoS ONE (2017) Vol. 12, Iss. 10, pp. e0185862-e0185862
Open Access | Times Cited: 83
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq
Tobias Gerber, Edith Willscher, Henry Loeffler‐Wirth, et al.
Oncotarget (2016) Vol. 8, Iss. 1, pp. 846-862
Open Access | Times Cited: 75
Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma
Leonardo Vinícius Monteiro de Assis, Gabriela Sarti Kinker, Maria Nathália Moraes, et al.
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 68
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
François Ghiringhelli, Jean-David Fumet
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 62
Metformin and trametinib have synergistic effects on cell viability and tumor growth inNRASmutant cancer
Igor Vujic, Martina Sanlorenzo, Christian Posch, et al.
Oncotarget (2014) Vol. 6, Iss. 2, pp. 969-978
Open Access | Times Cited: 63
Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach
Shirly Grynberg, Marilena Vered, Ronnie Shapira‐Frommer, et al.
JNCI Journal of the National Cancer Institute (2023) Vol. 116, Iss. 4, pp. 539-546
Closed Access | Times Cited: 14
AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment
Emilia Caputo, Roberta Miceli, Maria Letizia Motti, et al.
Journal of Translational Medicine (2014) Vol. 12, Iss. 1
Open Access | Times Cited: 48
Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock
Shilin Du, Yuan Xue, Zhan Sun, et al.
Biochemical and Biophysical Research Communications (2015) Vol. 458, Iss. 3, pp. 667-673
Closed Access | Times Cited: 43
Non-Metastatic Cutaneous Melanoma Induces Chronodisruption in Central and Peripheral Circadian Clocks
Leonardo Vinícius Monteiro de Assis, Maria Nathália Moraes, Keila Karoline Magalhães-Marques, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 4, pp. 1065-1065
Open Access | Times Cited: 38
Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma
Xiaomeng Zhang, Jian Tang, Ismael A. Vergara, et al.
Molecular Cancer Research (2019) Vol. 17, Iss. 7, pp. 1435-1449
Open Access | Times Cited: 33
The molecular clock in the skin, its functionality, and how it is disrupted in cutaneous melanoma: a new pharmacological target?
Leonardo Vinícius Monteiro de Assis, Maria Nathália Moraes, Ana Maria de Lauro Castrucci
Cellular and Molecular Life Sciences (2019) Vol. 76, Iss. 19, pp. 3801-3826
Open Access | Times Cited: 31
A Review of Advanced Cutaneous Melanoma Therapies and Their Mechanisms, from Immunotherapies to Lysine Histone Methyl Transferase Inhibitors
Renato Santos de Oliveira Filho, Daniel Arcuschin de Oliveira, Melissa Maeda Nisimoto, et al.
Cancers (2023) Vol. 15, Iss. 24, pp. 5751-5751
Open Access | Times Cited: 9
The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia
Katja Seipel, Miguel A. T. Marques, Corinne Sidler, et al.
Cancers (2018) Vol. 10, Iss. 6, pp. 170-170
Open Access | Times Cited: 27
Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance
Dipali Patel, Yandong Gao, Kyungjin Son, et al.
Lab on a Chip (2015) Vol. 15, Iss. 24, pp. 4614-4624
Closed Access | Times Cited: 26
Mutant NRASQ61 shares signaling similarities across various cancer types - potential implications for future therapies
Igor Vujic, Christian Posch, Martina Sanlorenzo, et al.
Oncotarget (2014) Vol. 5, Iss. 17, pp. 7936-7944
Open Access | Times Cited: 24
Recent advances in the treatment of melanoma with BRAF and MEK inhibitors.
Eva Muñoz‐Couselo, Jesús Soberino García, José Manuel Pérez-García, et al.
PubMed (2015) Vol. 3, Iss. 15, pp. 207-207
Closed Access | Times Cited: 23
Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor
Junya Yan, Xiaowen Wu, Jiayi Yu, et al.
European Journal of Cancer (2017) Vol. 89, pp. 90-101
Closed Access | Times Cited: 23
The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine
Kyle Crassini, William Stevenson, Stephen P. Mulligan, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2015) Vol. 56, Iss. 12, pp. 3407-3417
Closed Access | Times Cited: 16
Metastatic melanoma: Pathologic characterization, current treatment, and complications of therapy
Mark R. Wick, Alejandro A. Gru
Seminars in Diagnostic Pathology (2016) Vol. 33, Iss. 4, pp. 204-218
Closed Access | Times Cited: 12
Validating malignant melanoma ICD-9-CM codes in Umbria, ASL Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study
Massimiliano Orso, Diego Serraino, Iosief Abraha, et al.
BMJ Open (2018) Vol. 8, Iss. 4, pp. e020631-e020631
Open Access | Times Cited: 12
Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors
S. Mudan, Kumar Jayant, Neves C. Mafalda, et al.
Medicine (2017) Vol. 96, Iss. 49, pp. e9106-e9106
Open Access | Times Cited: 9
Page 1 - Next Page

Scroll to top